TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

Madeleine Duvic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.